摘要
免疫性血小板减少性紫癜(ITP)是最常见的自身免疫性疾病,是由抗体介导的血小板和巨核细胞-血小板生成受损产生的。ITP是一种排除性诊断。最近ITP的病理生理机制和治疗方法已开始出现。虽然类固醇和静脉注射免疫球蛋白(IVIg)仍然是主要的治疗策略,一组患者最终产生了耐药性,尤其是近十年已经有一些生物治疗方案,如利妥昔单抗。在这篇综述中,我们总结了ITP患者的治疗方案,主要集中在时间和生物制剂的潜在影响。
关键词: 自身免疫性疾病,生物治疗,免疫性血小板减少性紫癜,利妥昔单抗。
Current Medicinal Chemistry
Title:Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease
Volume: 22 Issue: 16
Author(s): Melda Comert Ozkan, Fahri Sahin and Guray Saydam
Affiliation:
关键词: 自身免疫性疾病,生物治疗,免疫性血小板减少性紫癜,利妥昔单抗。
摘要: Immune Thrombocytopenic Purpura (ITP) is the most common autoimmune disorder that is caused by antibody- mediated destruction of thrombocytes and impaired megakaryocyte platelet production. ITP remains a diagnosis of exclusion. Recent pathophysiologic mechanisms and therapeutical approaches of ITP have emerged. Although steroids and intravenous immunglobulins (IVIg) have still been the main therapeutic strategies, a group of patients develop resistance to those eventually and there have been some biological treatment options such as rituximab especially in the last decade. In this review article, we have summarized the therapeutic options for patients with ITP and mainly focused on the timing and potential effects of biological agents.
Export Options
About this article
Cite this article as:
Melda Comert Ozkan, Fahri Sahin and Guray Saydam , Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease, Current Medicinal Chemistry 2015; 22 (16) . https://dx.doi.org/10.2174/0929867322666150319102830
DOI https://dx.doi.org/10.2174/0929867322666150319102830 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nature and Nurture in the Early-Life Origins of Metabolic Syndrome
Current Pharmaceutical Biotechnology Rheumatoid Arthritis: Notable Biomarkers Linking to Chronic Systemic Conditions and Cancer
Current Pharmaceutical Design N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
Current Alzheimer Research The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design Biologics for the Treatment of Juvenile Idiopathic Arthritis
Current Medicinal Chemistry Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy
CNS & Neurological Disorders - Drug Targets Mechanisms of Inflammatory Atherosclerosis in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) Proteostasis, an Emerging Therapeutic Paradigm for Managing Inflammatory Airway Stress Disease
Current Molecular Medicine Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry Antitumoral Alkylphospholipids Alter Cell Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
Current Pharmaceutical Design Magnetic Resonance Angiography and Multidetector CT Angiography in the Diagnosis of Takayasu's Arteritis: Assessment of Disease Extent and Correlation with Disease Activity
Current Medical Imaging Bergenin - A Biologically Active Scaffold: Nanotechnological Perspectives
Current Topics in Medicinal Chemistry New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Lectin-Like Oxidized Low Density Lipoprotein Receptor 1 (LOX-1) in Atherogenesis: A Brief Review
Current Medicinal Chemistry The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Foreword: The Year in Review: Comments on Plants, Cyclodextrins, Microbiota, and Diabetes
Current Pharmaceutical Design Treatment of HCV-Related Mixed Cryoglobulinemia
Current Drug Targets Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases
Current Pharmaceutical Design The Relationship between Inflammatory and Oxidative Stress Biomarkers, Atherosclerosis and Rheumatic Diseases
Current Pharmaceutical Design